Matthew R. Zibelman, MD, is a genitourinary medical oncologist at Fox Chase Cancer Center in Philadelphia, PA, where he specializes in renal cell carcinoma and urothelial carcinoma with a particular clinical and research interest in immunotherapy.
Dr. Zibelman has published numerous articles on immunotherapy for GU cancers and is the principal investigator for two ongoing, investigator-initiated combination immunotherapy trials. He is also the PI for a grant geared at standardizing management of immune-related adverse events across his institution, utilizing and then providing immunotherapy event management education to patients, staff, and non-oncologists using a variety of media platforms.
He received his medical school training from Temple University in Philadelphia and completed his fellowship training in medical oncology at Fox Chase Cancer Center.
